BioCentury
ARTICLE | Finance

Betting on Biclonics

Merus adds 3d strategic investor before bispecific antibodies enter clinic

October 14, 2013 7:00 AM UTC

Merus B.V. attracted a trio of pharma investors to its €31 million ($41.9 million) extension of a series B round, which it hopes will be enough to move its lead bispecific cancer antibodies into the clinic.

New investor Johnson & Johnson Development Corp. participated in the extension, along with existing investors Novartis Venture Fund; Pfizer Venture Investment; Bay City Capital; LSP-Life Sciences Partners; and Aglaia Oncology Fund. The extension brings the total secured in the round to €47.6 million ($64.4 million)...